Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AstraZeneca’s Vaxzevria COVID-19 vaccine wins full authorization in Europe

By Brian Buntz | November 2, 2022

AstraZeneca in the Drug Discovery & Development Pharma 50Although not available in the U.S., AstraZeneca’s (LON:AZN) Vaxzevria COVID-19 vaccine has won full marketing authorization in the European Union.

European authorities initially granted conditional marketing authorization to the vaccine for individuals at least 18 years old in early 2021. However, in April, the European Medicines Agency (EMA) noted that the vaccine had a possible link to rare cases of blood clots with low platelet levels. Johnson & Johnson’s COVID-19 vaccine was linked to similar reports.

European regulators’ decision to grant full authorization to the AstraZeneca vaccine follows a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP).

The marketing authorization covers the use of the vaccine for primary vaccination and as a heterologous or homologous booster.

European regulatory authorities decided to provide full authorization for the vaccine after reviewing data from four clinical trials in the UK, Brazil and South Africa. The data indicated that the vaccine was safe and effective at protecting against COVID-19 in adults. The total sum of clinical trial data involved about 24,000 people, with nearly one-half of the population receiving two doses of the Vaxzevria vaccine and the other half getting two doses of a dummy vaccine.

The trial data concluded that the vaccine led to a 59.5% reduction in symptomatic COVID-19 cases relative to those given control injections. Thus, the vaccine had approximately 60% efficacy in clinical trials.

“The move from conditional to full marketing authorization for Vaxzevria is an important confirmation by the EMA of the safety and efficacy of Vaxzevria, demonstrating that the benefits continue to outweigh the potential risks,” said Iskra Reic, executive vice president of vaccines and immune therapies, AstraZeneca, in a news release. “Vaxzevria is estimated to have helped save over six million lives in the first year of vaccination, which reflects the strength of the evidence showing Vaxzevria’s protection against severe disease and death caused by COVID-19.”

AstraZeneca stock ticked up almost a percentage point to £10,346.00 yesterday.

To date, the Vaxzevria vaccine has been the subject of more than 300 studies, according to AdisInsight.


Filed Under: Infectious Disease
Tagged With: AstraZeneca, Vaxzevria
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Close-up medical syringe with a vaccine.
Six leading medical organizations sue RFK Jr. over vaccine recommendations
RFK’s new ACIP changed longstanding vaccine recommendations
Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE